PCSK9 and diabetes mellitus: Although, some Mendelian randomization analyses concomitant with post-marketing monitoring reports evidence of mild increase of hyperglycemia, rather than diabetes, in the first 6 months of the therapy with PCSK9 inhibitors (197).